RxDoctor Payments Data

Bridget Westerman, PA

Physician Assistant · Buffalo, NYNPI 1356919849

Payments from drug & device makers

$6,247in general payments, 2019–2025

Across 433 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • QOL Medical, LLC$736
  • Takeda Pharmaceuticals U.S.A., Inc.$567
  • Bristol Myers Squibb$409
  • Pfizer$369
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$6,05697%
  • Education$1913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,247 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$15,948
Medicare patients
117
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab36$1,062,616
XifaxanRifaximin60$205,300
CreonLipase/Protease/Amylase64$156,793
LinzessLinaclotide163$122,734
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres23$101,477
TrulancePlecanatide38$25,209
Mesalamine34$23,028
MotegrityPrucalopride Succinate32$19,399
VoqueznaVonoprazan Fumarate18$18,869
Dexlansoprazole DrDexlansoprazole31$12,559
MovantikNaloxegol Oxalate20$9,880
Mesalamine ErMesalamine13$9,605
Sucralfate89$9,228
Famotidine416$6,995
Lubiprostone30$6,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,540$1,062,61636 claims
AbbVieCreon, Linzess$300$279,528227 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,306$230,51098 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$567$19,39932 claims
Phathom Pharmaceuticals, Inc.Voquezna$125$18,86918 claims
Redhill Biopharma Inc.Movantik$17$9,88020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →